Pages that link to "Q27025648"

The following pages link to Small-molecule inhibitors of the Myc oncoprotein (Q27025648):

Displaying 47 items.

• Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1. (Q27349131) (← links)
• Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids (Q30278518) (← links)
• Role of MYC in B Cell Lymphomagenesis. (Q33608499) (← links)
• Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells (Q33728292) (← links)
• MYC Deregulation in Primary Human Cancers. (Q33836755) (← links)
• Aspirin and salicylic acid decrease c-Myc expression in cancer cells: a potential role in chemoprevention (Q34491262) (← links)
• Binding cavities and druggability of intrinsically disordered proteins (Q35571730) (← links)
• Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines (Q35601876) (← links)
• BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536 (Q35697342) (← links)
• microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13. (Q35937111) (← links)
• Small molecules, big targets: drug discovery faces the protein-protein interaction challenge (Q35981250) (← links)
• Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion (Q36140644) (← links)
• Strategies to Inhibit Myc and Their Clinical Applicability (Q36303678) (← links)
• MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation (Q37118720) (← links)
• MicroRNA-based screens for synthetic lethal interactions with c-Myc (Q37495218) (← links)
• JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer (Q37687075) (← links)
• Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts (Q37733990) (← links)
• Lysine-52 stabilizes the MYC oncoprotein through an SCF(Fbxw7)-independent mechanism (Q38625813) (← links)
• Drugging the 'undruggable' cancer targets (Q38667658) (← links)
• Targeting MYC: is it getting any easier? (Q38819081) (← links)
• The MYCN Protein in Health and Disease (Q39208675) (← links)
• MYC Modulation around the CDK2/p27/SKP2 Axis (Q39406924) (← links)
• Family matters: How MYC family oncogenes impact small cell lung cancer. (Q39454070) (← links)
• A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors (Q41880916) (← links)
• Small molecules remain on target for c-Myc (Q42329646) (← links)
• In silico structure-based approaches to discover protein-protein interaction-targeting drugs (Q47960281) (← links)
• Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction. (Q52596648) (← links)
• Too many targets, not enough patients: rethinking neuroblastoma clinical trials. (Q52597787) (← links)
• The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues. (Q52715807) (← links)
• Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. (Q55049313) (← links)
• MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability (Q58327191) (← links)
• The Biological Significance and Regulatory Mechanism of c-Myc Binding Protein 1 (MBP-1) (Q60919628) (← links)
• Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches (Q60926326) (← links)
• Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer (Q64054852) (← links)
• MYC Oncogene Contributions to Release of Cell Cycle Brakes (Q64061957) (← links)
• Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies (Q64087496) (← links)
• Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy (Q64091307) (← links)
• Reactive Chemicals and Electrophilic Stress in Cancer: A Minireview (Q88494621) (← links)
• Targeting Transcription Factors for Cancer Treatment (Q89157968) (← links)
• A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation (Q89399700) (← links)
• Dynamic conformational flexibility and molecular interactions of intrinsically disordered proteins (Q89535892) (← links)
• HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1 (Q90334452) (← links)
• A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization (Q90438681) (← links)
• Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers (Q90748016) (← links)
• CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression (Q91494245) (← links)
• C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer (Q92604978) (← links)
• The MAP3K13-TRIM25-FBXW7α axis affects c-Myc protein stability and tumor development (Q92667854) (← links)